Rebecca Halpin

机构：AstraZeneca (Japan), AstraZeneca (United States) · ORCID：0000-0002-2267-2145

发表论文 186 篇 · 总被引 8837 次 · h-index 50

代表论文

• H19 influenza A virus exhibits species-specific MHC class II receptor usage (2024 · Cell Host & Microbe · 被引 97)
• Comprehensive cellular analysis with single-nucleus RNA-seq of archived PAXgene whole blood samples (2026 · Cell Reports Methods · 被引 1)
• Abstract 5546: Rilvegostomig elicits greater immune activation and tumor inhibition than clinically approved anti-PD-1 monotherapy in models of HNSCC (2026 · Cancer Research)
• 470 Multimodal profiling reveals unique and overlapping features of rilvegostomig and PD(x) activity in NSCLC tumor explants (2025 · Regular and Young Investigator Award Abstracts)
• Cell lysis plus depletion single-nucleus RNA-seq (CL-D snRNAseq) v1 (2025)
• Comprehensive cellular analysis with single-nucleus RNA-seq of archived PAXgene whole blood samples (2025 · bioRxiv (Cold Spring Harbor Laboratory))